Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or ...
Krystal Biotech reports positive clinical data for KB408 and KB407, demonstrating safety and efficacy in AATD and cystic fibrosis patients. Krystal Biotech, Inc. has announced promising clinical ...
A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...
Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of ...
Researchers at the Jackson Laboratory (JAX), the Broad Institute of MIT and Harvard, and Yale University, have used artificial intelligence (AI) to design thousands of new DNA switches that can ...
Single cell gene expression studies often rely on single-cell RNA sequencing (scRNA-seq) alone. While scRNA-seq reveals which genes are turned on, it does not capture protein expression or changes to ...
Morning Overview on MSN
Gene hacking is coming and it could rewrite what it means to be human
For the first time, the tools to rewrite human biology are moving from speculative fiction into regulated clinics and ...
GlobalData on MSN
Genespire to take rare disease gene therapy to clinic in 2026
GENE202 is a single dose gene therapy for patients with rare metabolic disease, methylmalonic acidaemia.
AZoLifeSciences on MSN
Life science and biotech trends for 2026
Advancements in AI, multi-omics, and genome editing are transforming life sciences and biotechnology, addressing new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results